Apontis Pharma AG
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
APPH | F
Overview
Corporate Details
- ISIN(s):
- DE000A3CMGM5 (+1 more)
- LEI:
- 894500ETO1J6MR8PDF91
- Country:
- Germany
- Address:
- Alfred-Nobel-Straße 10, 40789 Monheim am Rhein
- Website:
- https://apontis-pharma.de/en/
- Sector:
- Manufacturing
Description
Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-20 16:00 |
APONTIS PHARMA: Changes in the management board
|
English | 9.1 KB | ||
| 2025-08-19 00:00 |
Half-yearly financial statements 2025
|
English | 712.8 KB | ||
| 2025-06-13 10:30 |
APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
|
English | 7.2 KB | ||
| 2025-05-15 07:30 |
APONTIS PHARMA publishes results for the first quarter of 2025 and confirms for…
|
English | 25.5 KB | ||
| 2025-03-31 14:00 |
APONTIS PHARMA with significant sales and earnings increase in 2024 financial y…
|
English | 26.3 KB | ||
| 2025-03-31 00:00 |
Annual financial statements 2024
|
English | 1.3 MB | ||
| 2025-03-06 20:50 |
APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger sque…
|
English | 7.6 KB | ||
| 2025-03-05 20:50 |
APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger sque…
|
English | 7.6 KB | ||
| 2024-12-23 00:00 |
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
|
German | 27.9 KB | ||
| 2024-12-12 14:42 |
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody acc…
|
English | 7.7 KB | ||
| 2024-12-11 16:00 |
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody acc…
|
English | 7.7 KB | ||
| 2024-12-10 10:35 |
APONTIS PHARMA AG: Thomas Zimmermann, sell
|
English | 7.5 KB | ||
| 2024-11-27 00:00 |
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
|
German | 398.4 KB | ||
| 2024-11-22 11:30 |
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public…
|
English | 14.2 KB | ||
| 2024-11-21 11:30 |
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public…
|
English | 14.2 KB |
Automate Your Workflow. Get a real-time feed of all Apontis Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Apontis Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Apontis Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-14 | Milz, Thomas | Board | Buy | None | 8,960.00 EUR |
| 2024-05-14 | be executive GmbH | Close relation | Buy | None | 8,880.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 10,128.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 3,396.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,692.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,688.00 EUR |
| 2023-05-05 | Reineke, Silke | Close relation | Buy | None | 36,625.00 EUR |
| 2023-05-05 | Milz, Thomas | Board | Buy | None | 14,360.00 EUR |
Peer Companies
